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Clinical trials and experimental studies have highlighted the
importance of epigenetic processes in the development of
diabetic complications. One of the earliest features of
diabetic nephropathy is renal enlargement. The epidermal
growth factor (EGF) has a pivotal role in the development of
diabetic nephromegaly and transactivation of its receptor has
been implicated in the pathogenesis of later-stage disease.
As EGF signaling is altered by the acetylation status of
histone proteins, we measured the effects of the histone
deacetylase (HDAC) inhibitor, vorinostat, in mediating renal
enlargement in diabetes focusing on the EGF–EGF receptor
(EGFR) axis. In cultured proximal tubule (normal rat kidney)
cells, vorinostat treatment reduced EGFR protein and mRNA,
and attenuated cellular proliferation. Within 72h of diabetes
induction with streptozotocin, urinary EGF excretion was
increased approximately threefold and was unaffected by
vorinostat, even though the kidneys of vorinostat-treated
diabetic rats had reduced tubular epithelial cell proliferation.
Daily treatment of diabetic rats with vorinostat for 4 weeks
blunted renal growth and glomerular hypertrophy. Thus,
early renal changes in diabetes are amenable to epigenetic
intervention. Attenuating effects of HDAC inhibition,
although multifactorial, are likely to be mediated in part
through downregulation of the EGFR.
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Over recent years, reporting of the long-term follow-up of
patients involved in landmark clinical trials of diabetes has
highlighted the importance of epigenetic processes in the
pathogenesis of diabetic complications. In patients with either
type 1 or type 2 diabetes, early, intensive glycemic control
reduces the risk of both microvascular and macrovascular
diseases up to a decade after glycemic separation between
intensive and usual care groups is no longer apparent.1,2 This
phenomenon, termed the ‘legacy effect,’ seems at this stage to be
confined to glycemia with no evidence of a similar ‘memory’ for
blood pressure control.3 Experimental studies in cultured cells
and rodents have begun to shed light on the mechanisms
underlying this paradigm,4,5 with focus on non-genomic changes
in gene expression.
Among epigenetic mechanisms, modification of the
acetylation status of e-amino groups of lysine residues in
nucleosome histone tails is the most advanced in terms of
drug development. Histone acetylation and deacetylation
are modulated by groups of enzymes known as histone
acetyltransferases and histone deacetylases (HDACs), respec-
tively.6,7 In 2003, studies in an experimental model of lupus
nephritis demonstrated the potential anti-proteinuric prop-
erties of the broad-spectrum HDAC inhibitor (HDACi),
trichostatin A.8 Since that time, the anti-fibrotic and anti-
proliferative effects of HDACis in kidney disease have been
supported by several other in vitro and in vivo studies.9–12
In particular, a daily subcutaneous injection of trichostatin A
significantly attenuated proteinuria in streptozotocin (STZ)-
diabetic rats.13
Although clinically, the first evidence of diabetic nephro-
pathy is often the development of an increase in urine
albumin excretion, several changes in the renal structure and
function often precede this and usually go undetected. For
example, renal enlargement is a characteristic feature of both
human14 and experimental diabetes15,16 and may be pre-
dictive of future development of clinically significant renal
impairment.17,18 Although the precise mechanisms respon-
sible for renal enlargement in diabetes are incompletely
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understood, our previous studies have highlighted a pivotal
role for the epidermal growth factor (EGF)–EGF receptor
(EGFR) axis.19,20 The expression of EGF within the kidney is
increased within 24 h of the induction of diabetes with STZ,19
and administration of a small molecule EGFR tyrosine kinase
inhibitor attenuated renal enlargement at 3 weeks.20
In this study, we took advantage of a recently approved
HDACi, vorinostat (suberoylanilide hydroxamic acid) that
has been shown to decrease the expression of the EGFR in
cultured cell lines,21 hypothesizing that this agent would
attenuate EGF-mediated tubular epithelial cell proliferation
and thereby renal enlargement in early experimental diabetes.
RESULTS
Effect of vorinostat on tubular cell proliferation in vitro
As proximal tubule cell proliferation is the primary process
underlying the nephromegaly of early diabetes, we first
examined the effect of HDAC inhibition with vorinostat on
cultured proximal tubule lineage normal rat kidney (NRK)
cells. Treatment of NRK cells with 5 mmol/l vorinostat for
24 h antagonized the actions of HDACs as indicated by a
marked increase in histone H3 acetylation (Figure 1a).
Recognizing the fact that HDAC inhibition has the potential to
alter several signaling pathways within the cell, we investigated
the effect of vorinostat in the setting of cellular proliferation
induced by high glucose (25 mmol/l), EGF, or insulin-like
growth factor-1 (IGF-1), the latter two proteins being growth
factors previously implicated in early diabetic renal enlarge-
ment.20,22 In an MTT proliferation assay, exposure of NRK cells
to high glucose, recombinant EGF, or recombinant IGF-1
caused an increase in cellular proliferation (Figure 1b). Whereas
vorinostat attenuated the increase in cellular proliferation in
response to high glucose and EGF, it had no effect on IGF-1-
mediated cellular proliferation (Figure 1b).
Vorinostat downregulates the EGFR in cultured NRK cells
As both EGF and high glucose may transactivate the EGFR
and as vorinostat has previously been reported to down-
regulate this receptor,21 we set out to further examine this
pathway in NRK cells. Treatment of NRK cells with 1 nmol/l
recombinant EGF for 24 h did not result in significant cellular
hypertrophy (protein:DNA ratio, control (a.u.) 1.00±0.15,
EGF 1.25±0.09, P¼ 0.22). Vorinostat treatment of NRK
cells for 24 h caused a dose-dependent decrease in the EGFR
protein (Figure 2a), associated with a reduction in phos-
phorylated EGFR (Figure 2b) and an B50% decrease in
EGFR mRNA (Figure 2c).
Effect of vorinostat on tubular epithelial cell proliferation
in vivo
Having demonstrated attenuation of EGF signaling in vitro,
we next went on to examine the effect of vorinostat on
tubular cell proliferation in vivo. Treatment of normal rats
with vorinostat for 5 days resulted in a significant 15%
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Figure 1 | Effect of vorinostat on histone acetylation and
cellular proliferation. (a) Effect of vorinostat (5 mmol/l) on
acetylation of histone H3. (b) Role of vorinostat in mediating NRK
cell proliferation as determined by MTT assay in the presence of
EGF (1 nmol/l), high glucose (25mmol/l), mannitol (19.4mmol/l),
or IGF-1 (13 nmol/l). Mean of at least three experiments. *Po0.001
vs EGFþ vorinostat, wPo0.01 vs high glucoseþ vorinostat. EGF,
epidermal growth factor; IGF-1, insulin-like growth factor-1; NRK,
normal rat kidney.
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Figure 2 | Effect of vorinostat on EGFR expression in vitro and
in vivo. (a) Total EGFR, (b) phosphorylated EGFR, and (c) EGFR
mRNA in cultured NRK cells. (d) EGFR mRNA in kidney
homogenates obtained from rats treated with vehicle or
vorinostat (50mg/kg) for 5 days (n¼ 9 per group). *Po0.05 vs
control, wPo0.01 vs control, zPo0.05 vs vehicle. EGFR, epidermal
growth factor receptor; NRK, normal rat kidney.
Kidney International (2011) 79, 1312–1321 1313
RE Gilbert et al.: HDACs and diabetic nephromegaly o r ig ina l a r t i c l e
reduction in renal EGFR mRNA in whole-kidney homo-
genates (Figure 2d). As maximal tubular cell proliferation
occurs within the first 72 h of induction of diabetes with
STZ, we therefore treated Sprague Dawley rats with either
vorinostat (50 mg/kg) or vehicle by daily oral gavage,
commencing 2 days before a tail-vein injection of STZ
(or citrate buffer control) and continuing for a further 3 days.
Vorinostat had no effect on blood glucose in either control or
diabetic animals (Table 1). At 3 days, tubular epithelial cell
proliferation was markedly increased in diabetic animals and
was reduced with vorinostat, as determined by either Ki-67
immunostaining (Figure 3a–e) or 5-bromo-20-deoxyuridine
(BrdU) incorporation (Figure 3f–j).
Vorinostat downregulates the EGFR in the kidneys
of diabetic rats
To unravel the relationship between body weight, kidney
growth, and EGFR expression in response to vorinostat
treatment, Sprague Dawley rats were treated with varying
doses of vorinostat (0–100 mg/kg per day) for 5 days, with
diabetes induced with a tail-vein injection of STZ on day 3.
Over this time period, although vorinostat treatment did not
Table 1 | Functional characteristics of Sprague Dawley rats treated with vorinostat for 5 days and made diabetic with STZ on
day 3 (n=9 per group)
Body weight (g) Blood glucose (mmol/l) Mean kidney weight (g) Kidney weight, body weight (%)
Control+vehicle 342±16 7.1±0.3 1.09±0.03 0.32±0.01
Control+vorinostat 332±18 8.0±0.3 1.04±0.05 0.32±0.01
Diabetic+vehicle 301±15 28.1±0.9*w 1.19±0.04z 0.40±0.01*w
Diabetic+vorinostat 286±13 29.1±1.3*w 1.07±0.03 0.38±0.01yz
Abbreviation: STZ, streptozotocin.
*Po0.001 vs control+vehicle, wPo0.001 vs control+vorinostat, zPo0.05 vs control+vorinostat, yPo0.01 vs control+vehicle, and zPo0.01 vs control+vorinostat.
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Figure 3 | Effect of vorinostat treatment on tubular epithelial cell proliferation in vivo. (a–d) Representative photomicrographs
of Ki-67 immunostaining in kidney sections obtained from Sprague Dawley rats 3 days after the induction of diabetes.
(a) Controlþ vehicle, (b) controlþ vorinostat, (c) diabeticþ vehicle, and (d) diabeticþ vorinostat. (e) Ki-67-positive nuclei per  160 field.
(f–i) Representative photomicrographs of BrdU incorporation in kidney sections obtained from Sprague Dawley rats 3 days after the
induction of diabetes, (f) controlþ vehicle, (g) controlþ vorinostat, (h) diabeticþ vehicle, (i) diabeticþ vorinostat. (j) BrdU-positive nuclei
per  160 field. Original magnification  160. n¼ 9 per group. *Po0.001 vs controlþ vehicle, wPo0.01 vs diabetesþ vehicle; Ki-67,
Po0.05 for interaction; BrdU, Po0.01 for interaction. BrdU, 5-bromo-20-deoxyuridine.
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alter body weight, it did cause a dose-dependent reduction in
the kidney weight:body weight ratio (Figure 4a–c). Associated
with the reduction in kidney growth, both EGFR mRNA and
protein were reduced in the kidneys of diabetic rats treated
with 50 mg/kg vorinostat, relative to their vehicle-treated
counterparts (Figure 4d).
Vorinostat attenuates early diabetic renal enlargement
To determine whether the attenuation of proximal tubular
cell proliferation with vorinostat translated to a reduction in
kidney mass, Sprague Dawley rats received a tail-vein
injection of STZ or citrate buffer and were treated with
vorinostat (50 mg/kg) or vehicle, by once daily oral gavage for
4 weeks. After 4 weeks of treatment, diabetic rats had reduced
body weight and increased systolic blood pressure than did
normoglycemic animals (Table 2). Immunoblotting of kidney
homogenates, revealed that both the total EGFR protein and
the phosphorylated EGFR were reduced in the kidneys of
diabetic rats treated with vorinostat for 4 weeks, in compa-
rison with vehicle-treated diabetic animals (Figure 5a).
Without affecting either blood glucose or blood pressure
(Table 2), vorinostat attenuated the increase in kidney weight
(considered either as total weight or corrected for body
weight) (Figure 5b and c) in STZ-diabetic rats.
Although decreased renal growth may be a consequence of
attenuated cellular proliferation, enhanced apoptosis may
also contribute. To investigate whether increased tubular
cell death also occurred with vorinostat treatment, terminal
deoxyuridine triphosphate nick-end labeling (TUNEL) was
performed on cultured NRK cells and on kidney sections
obtained from control and diabetic rats. Vorinostat did
not induce apoptosis, as indicated by TUNEL staining in
NRK cells (data not shown), whereas the number of
TUNEL-positive nuclei was increased in kidney sections
obtained from diabetic rats and reduced with vorinostat
(Figure 6).
Treatment of non-diabetic rats with vorinostat (50 mg/kg)
for 4 weeks was associated with a significant reduction in
body weight gain (Table 2). To further explore whether the
reduced weight gain with vorinostat was responsible for
attenuated renal enlargement at 4 weeks, diabetic rats
(n¼ 12) were treated with a lower dose of vorinostat
(20 mg/kg), which has previously been described to have no
effect on weight gain in Sprague Dawley rats.23 Although
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Figure 4 | Effect of vorinostat on body weight, kidney growth, and EGFR expression in diabetic rats. (a–c) Rats were treated
with vehicle or vorinostat in daily doses of 10, 20, 50, or 100mg/kg for 5 days, with diabetes induction after 48 h. Without affecting body
weight, vorinostat dose dependently reduced kidney weight: body weight ratio (c) (n¼ 6 per group). (d) EGFR protein and mRNA in the
kidneys of diabetic rats treated with vehicle or vorinostat (50mg/kg per day) for 5 days (n¼ 15 per group). *Po0.05 for linear trend,
wPo0.05 vs vehicle. EGFR, epidermal growth factor receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
Table 2 | Functional characteristics of Sprague Dawley rats
treated with vorinostat (50mg/kg) or vehicle for 4 weeks
(n=12 per group)
Body weight
(g)
Systolic BP
(mmHg)
Blood glucose
(mmol/l)
Control+vehicle 502±11 121±1 6.4±0.3
Control+vorinostat 423±5* 112±2 7.4±0.2
Diabetic+vehicle 300±7*w 138±5zw 30.4±0.7*w
Diabetic+vorinostat 278±7*w 132±4w 31.1±0.7*w
Abbreviation: BP, blood pressure.
*Po0.001 vs control+vehicle, wPo0.001 vs control+vorinostat, zPo0.01 vs
control+vehicle; body weight, Po0.001 for interaction.
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there was no difference in body weight between diabetic
animals receiving 20 mg/kg vorinostat and vehicle, renal
growth and glomerular hypertrophy were both reduced in the
vorinostat-treated group (body weight 306±6 g; kidney
weight 1.42±0.07 g, Po0.01 vs vehicle; kidney weight:body
weight ratio 0.46±0.02%, Po0.01 vs vehicle; glomerular
volume (GV) 0.96±0.02 106mm3, Po0.01 vs vehicle).
Urinary EGF excretion in control and diabetic rats treated
with vehicle or vorinostat
To investigate whether vorinostat altered the magnitude of
the renal EGF protein itself, urinary EGF excretion was
determined by ELISA (enzyme-linked immunosorbent assay)
(Figure 7). STZ diabetes resulted in an approximate three-
fold increase in urinary EGF at 3 days (Figure 7a). In
contrast, by 4 weeks, coincident with the cessation of hyper-
trophy, urine EGF excretion was slightly lower in diabetic rats
than in controls (Figure 7b). Although vorinostat was asso-
ciated with a marginal, non-significant reduction in urinary
EGF at 3 days, excretion of the growth factor still remained
markedly elevated in vorinostat-treated diabetic rats than in
controls (Figure 7a).
Effect of vorinostat on glomerular cells
Although downregulation of the EGFR may explain the
reduction in both tubular epithelial cell proliferation and
kidney mass with vorinostat, we considered that alternative
mechanisms of action would underlie any attenuation of
glomerular enlargement, which is predominantly mediated
by cellular hypertrophy rather than by hyperplasia.24 Indeed,
glomerular cell proliferation (determined by either Ki-67
immunostaining or BrdU incorporation) after 3 days of
diabetes was an infrequent event, detectable in o10% of
glomeruli and with no difference in magnitude among the
four treatment groups. GV was significantly reduced in
diabetic rats treated with vorinostat for 4 weeks than in their
vehicle-treated counterparts (Figure 8a). Similarly, glomeru-
lar capillary volume, determined by JG-12 immunostaining
was increased in diabetic rats and reduced with vorinostat
(Figure 8b–f), raising the possibility that the well-recognized
anti-angiogenic effects of this class of agents may mediate the
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Figure 5 | EGFR expression and kidney size after treatment
with vorinostat for 4 weeks. (a) Phosphorylated and total EGFR
in kidney homogenates obtained from control and diabetic
Sprague Dawley rats treated with vehicle or vorinostat (50mg/kg)
for 4 weeks. (b) Kidney weight and (c) kidney weight:body weight
ratio in control and diabetic rats treated with vehicle or vorinostat
for 4 weeks, n¼ 12 per group. *Po0.001 vs controlþ vehicle,
wPo0.001 vs diabetesþ vehicle, zPo0.05 vs controlþ vehicle;
kidney weight:body weight ratio, Po0.05 for interaction. EGFR,
epidermal growth factor receptor; GAPDH, glyceraldehyde
3-phosphate dehydrogenase.
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observed reduction in glomerular hypertrophy. Contrasting
the anti-hypertrophic effects in vivo, vorinostat treatment
resulted in an increase in the protein content of cultured
Sprague Dawley mesangial cells (protein:DNA ratio (a.u.),
control 1.00±0.08, vorinostat 1.46±0.07, Po0.01).
DISCUSSION
Although originally considered for their anti-cancer proper-
ties, a growing body of evidence supports the safety and
efficacy of HDACis in experimental models of cardiorenal
disease, potentially expanding their clinical application.7
Diabetic nephropathy is the most common cause of end-
stage renal disease in the Western world.25 In this regard, the
therapeutic potential of the broad-spectrum HDACi trichos-
tatin A has been suggested by studies in diabetic rats and in
cultured cells.13 However, trichostatin A is limited by low oral
bioavailability and a relatively short half-life in vivo.26,27
Moreover, until now, the majority of studies exploring the
role of HDAC inhibition in experimental models of kidney
disease have focused on anti-fibrotic mechanisms.10,11,13 In
this study, we explored the efficacy of the orally bioavailable
HDACi, vorinostat, in early experimental diabetic nephro-
pathy. Vorinostat prevented tubular cell proliferation in vitro
and in vivo and attenuated renal enlargement and glomerular
hypertrophy in diabetic rats. Consistent with experiments in
the neoplastic setting,21,28 these changes were, at least partly,
mediated by downregulation of the EGFR.
Although a range of locally active growth factors have
been implicated in early diabetes-related kidney growth, EGF
pre-eminently fulfills the criteria that establish the role of a
growth factor in kidney disease.29 Not only is EGF increased
in human and experimental diabetes but also its adminis-
tration increases kidney cell growth and its blockade reduces
it.20,30 In the present series of experiments, the broad-
spectrum HDACi, vorinostat, decreased EGFR expression
and attenuated tubular cell proliferation both in vitro and
in vivo. However, although vorinostat reduced kidney size, it
did not normalize it, suggesting that other growth factors
such as vascular endothelial growth factor,31 transforming
growth factor-b,32 and IGF-122 may also contribute to
diabetes-associated early kidney growth. Although the
mechanism for decreased EGFR expression with vorinostat
is uncertain, decreased mRNA stability may have a role. For
example, in a cultured breast cancer cell line, EGFR mRNA
was significantly reduced with vorinostat within 2 h after new
RNA synthesis was blocked with actinomycin D.21
Reduced kidney size may be a consequence of decreased
cell growth, increased cell death, or a combination of the two.
Treatment of diabetic rats with vorinostat attenuated tubular
cell proliferation in vivo. Although HDACis preferentially
promote tumor cell death, these agents typically show
remarkable selectivity with minimal cytotoxicity observed
in normal cells.33–35 In fact, in a unilateral ureteral obstruc-
tion model, trichostatin A actually decreased tubular cell
apoptosis9 and, in cultured cells, trichostatin A attenuated
cisplatin-induced cytotoxicity.36 In our experiments,
STZ-induced diabetes was associated with an increase in
tubular cell apoptosis, which is unlikely to be a consequence
of STZ toxicity.37 Treatment with vorinostat resulted in a
reduction in the number of TUNEL-positive nuclei, under-
scoring that the reduction in kidney size observed was not a
consequence of increased cell death. In our previous studies,
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Figure 8 | Effect of vorinostat-treatment on glomerular volume and capillary volume after 4 weeks. (a) Glomerular volume and (b–f)
JG-12 immunostaining in control and diabetic rats treated with vehicle or vorinostat for 4 weeks. (b) Controlþ vehicle, (c)
controlþ vorinostat, and (d) diabeticþ vehicle, (e) diabeticþ vorinostat. (f) Glomerular JG-12 labeling relative to controlþ vehicle. n¼ 12
per group. *Po0.05 vs controlþ vehicle, wPo0.001 vs diabetesþ vehicle, zPo0.01 vs controlþ vehicle; glomerular volume, Po0.05 for
interaction; JG-12 immunostaining, Po0.001 for interaction.
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inhibition of the EGFR tyrosine kinase was associated with
an increase in tubular epithelial cell apoptosis, although this
was not observed when the EGFR was downregulated with
vorinostat.20 Emerging evidence has revealed an important
role for EGFR signaling by nuclear translocation in addition
to classical cytoplasmic signaling pathways38 potentially
contributing to the differential effects of these two mechan-
isms of EGFR modulation.
Despite increasing mesangial cell protein content (indi-
cative of hypertrophy) in vitro, vorinostat treatment resulted
in a reduction in glomerular enlargement in vivo, a process
mediated primarily by changes in cell size rather than in cell
number.16 Although the observed reduction in glomerular
hypertrophy may be a consequence of decreased proximal
tubular bulk,39 direct effects of vorinostat on glomerular cells
may also have a role. One of the predominant features of
diabetic glomerulomegaly is an increase in glomerular
capillary volume,15,40,41 which is responsive to anti-angio-
genic therapies.42–44 Consistent with the known anti-
angiogenic effects of HDACis,45 vorinostat treatment was
associated with a significant reduction in glomerular
endothelial immunostaining. In this study, the finding of a
reduction in GV despite an increase in cell size in vitro
highlights that the in vivo effects of HDACis cannot
necessarily be predicted from in vitro findings and that these
effects are likely to involve multiple cellular pathways that
may be altered in the diabetic state.
The body weights of rats treated with vorinostat for
4 weeks were lower than those of their vehicle-treated
counterparts, reflecting the recognized effects of this agent on
body weight gain.23 However, treatment of diabetic rats with
vorinostat for 5 days (commencing 2 days before the
induction of diabetes) resulted in a dose-dependent attenua-
tion of renal enlargement independent of body weight
change, suggesting that the association between decreased
body weight gain and renal growth was not causal.
Vorinostat is a broad-spectrum inhibitor of class I and II
HDACs, with the potential to induce post-translational
modification of various non-histone proteins.46 Accordingly,
the attenuating properties of vorinostat on renal growth in
diabetes are unlikely to be mediated solely by downregulation
of the EGFR. It is interesting that it was recently shown that
specific targeting of HDAC6 resulted in the downregulation
of the EGFR and enhanced radiosensitization in cultured
human carcinoma cell lines.28 HDAC2 activity is increased in
the kidneys of STZ-diabetic rats and in db/db mice, and
small-interference RNA directed against this isoenzyme
prevented epithelial–mesenchymal transition in vitro.13 Our
experiments expand on this initial observation and define
that the therapeutic potential of HDAC inhibition in diabetic
nephropathy also includes modulation of epithelial cell
proliferation and renal growth.
Although EGFR activation is clearly implicated in the
renal enlargement of early diabetes, its effects in diabetic
nephropathy likely reach beyond this role. Numerous stimuli
may activate the EGFR, beyond EGF itself, including high
glucose.47 In this regard, it is noteworthy that NRK cell
proliferation was attenuated by vorinostat in response to
either high glucose or EGF, but not IGF-1. High glucose
transactivation of the EGFR also leads to upregulation of
serum glucocorticoid-regulated kinase-1, which may con-
tribute to tubular sodium reabsorption in diabetic nephro-
pathy.48 Similarly, collagen I induction by high glucose is
dependent on transactivation of the EGFR,49 and transacti-
vation of the receptor also mediates protein kinase C-b1
activation and transforming growth factor-b upregulation in
cultured mesangial cells.50 Signal transducer and activator
of transcription 3 is a transcription factor that undergoes
phosphorylation in response to EGFR-ligand binding
(among other receptors),51 and treatment of renal interstitial
fibroblasts with trichostatin A abolished signal transducer
and activator of transcription 3 signaling.9 Thus, not only are
the effects of vorinostat likely to extend beyond the
EGF–EGFR axis but also the attenuation of EGFR transacti-
vation is likely to have multiple effects beyond those on
cellular proliferation.
In summary, although the therapeutic potential of broad-
spectrum HDAC inhibition in renal diseases, such as diabetic
nephropathy, has largely been studied with respect to anti-
fibrotic effects, more widespread properties can be antici-
pated. In this study, we have demonstrated that the HDACi,
vorinostat, attenuated early renal enlargement in experi-
mental diabetes and that this effect is likely to be mediated, at
least in part, by downregulation of the EGFR.
MATERIALS AND METHODS
In vitro experiments
MTT cell proliferation assay. Subconfluent NRK cells were
cultured in Dulbecco’s modified Eagle’s medium (Multicell, Wisent,
St-Jean-Baptiste, QC, Canada).52 Cells were serum starved for 8 h
before supplementation of the culture medium with 5 mmol/l
vorinostat (Exclusive Chemistry, Obninsk, Russia) in DMSO
(dimethyl sulfoxide) or DMSO alone for 16 h. Culture media were
then supplemented with 1 nmol/l recombinant rat EGF (R&D
Systems, Minneapolis, MN), 19.4 mmol/l glucose (final concentra-
tion 25 mmol/l), 19.4 mmol/l mannitol, or 13 nmol/l recombinant
rat IGF-1 (R&D Systems) for a further 24 h. Cell proliferation
was determined using an MTT cell proliferation assay (ATCC,
Manassas, VA).
Protein:DNA ratio
The protein:DNA ratio was determined in cultured NRK cells and
Sprague Dawley mesangial cells.52 DNA was isolated using a
GenElute Mammalian DNA Miniprep kit (Sigma, Oakville, ON,
Canada) and quantitated using a Quant-iT PicoGreen dsDNA Assay
kit (Invitrogen, Carlsbad, CA). Protein content was determined
using a Bio-Rad DC Protein Assay kit (Bio-Rad, Hercules, CA).
NRK cells were treated with 1 nmol/l recombinant rat EGF for 24 h
as described previously. Cultured mesangial cells were incubated
with vorinostat (5mmol/l) for 24 h.
Immunoblotting
To determine the effect of vorinostat on histone H3 acetylation,
EGFR protein, and EGFR mRNA, cultured NRK cells were serum
1318 Kidney International (2011) 79, 1312–1321
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starved overnight and then treated for 24 h with vorinostat in
DMSO at the concentrations described. Protein was isolated from
cultured cell extracts with cell lysis buffer (Cell Signaling, Danvers,
MA) containing 1 mmol/l phenylmethylsulfonyl fluoride. Frozen rat
kidney tissue (nX3 per group) was homogenized (Polytron,
Kinematica Gmbh, Littau, Switzerland) in the cell lysis buffer
(Cell Signaling). Immunoblotting was performed with primary
antibodies in the following concentrations: acetyl histone H3 (Lys9)
1:1000 (Cell Signaling), total histone H3 1:1000 (Cell Signaling),
EGFR 1:1000 (Cell Signaling), phospho-EGFR 1:1000 (Cell Signaling),
b-actin 1:5000 (Abcam, Cambridge, MA), GAPDH (glyceraldehyde
3-phosphate dehydrogenase) 1:2000 (Abcam).
Real-time PCR
RNA was isolated from cultured cell lysates and kidney homogenates
using TRIzol reagent (Life Technologies, Grand Island, NY). Total
RNA (4mg) was treated with RQ1 DNAse (1 Units/ml) (Promega,
Madison, WI) to remove genomic DNA. RNA was reverse
transcribed using a High-Capacity cDNA reverse-transcription kit
(Applied Biosystems, Foster City, CA) according to the manufac-
turer’s instructions. Measurement of EGFR mRNA was performed
using SYBR green on an ABI Prism 7900HT Fast PCR System
(Applied Biosystems). Sequence-specific primers were obtained
from ACGT (Toronto, ON, Canada). Primer sequences were: 18S,
forward ATGTGGTGTTGAGGAAAGCAGAC, reverse GGATCTT
GTATTGTCGTGGGTTCTG; GAPDH, forward GTGCAGTGCCAG
CCTCGTC, reverse GGCAGCACCAGTGGATGCAG; and EGFR,
forward ATTCTTTCACCCGCACTCC, reverse GACAACCGCCAG
AGAAAAC. Experiments were performed in triplicate and data
analysis was performed using the Applied Biosystems comparative
CT method.
In vivo experiments
Study 1. Male Sprague Dawley rats aged 8 weeks were
randomized to receive either vorinostat (in the doses described) or
vehicle (0.5% methylcellulose (wt/vol) and 0.1% Tween 80 (vol/vol)) by
once daily oral gavage. Two days later, animals were randomized to
receive either a tail-vein injection of STZ (50 mg/kg) in 0.1 mol/l
sodium citrate buffer (pH 4.5) or citrate buffer alone, after an overnight
fast. Animals were followed up for a total of 5 days (that is, 72 h after
the induction of diabetes). Rats received a single intraperitoneal
injection of BrdU (10 mg/ml) (Sigma) 2 h before killing, to label cells in
the DNA synthetic (S) phase of the cell cycle.
Study 2. Male Sprague Dawley rats (weighing 320±2 g) were
randomized to receive either a tail-vein injection of STZ or citrate
buffer alone as described previously. The next day, animals were further
randomized to receive vorinostat (20 or 50 mg/kg) for 4 weeks.
Diabetic rats received a thrice weekly injection of insulin (1–4 Units
subcutaneously; Humulin N isophane; Eli Lilly Canada, Toronto, ON,
Canada). Blood glucose was determined using Accu-check Advantage
(Roche, Mississauga, ON). Systolic blood pressure was recorded by tail-
cuff plethysmography.52,53 Urinary EGF was determined using a rat
EGF Duoset ELISA Development kit (R&D Systems).
All experimental procedures adhered to the guidelines of
the Canadian Council on Animal Care and were approved by
St Michael’s Hospital Animal Care Committee.
Immunohistochemistry
Immunohistochemistry was performed as described previously,52–54
with antibodies at the following concentrations: Ki-67 1:100 (mouse
monoclonal anti-rat Ki-67 antigen, clone MIB-5, DakoCytomation,
Glostrup, Denmark), BrdU 1:500 (mouse monoclonal anti-BrdU
antibody, clone BU 33, Sigma), and JG-12 1:400 (Bender Medsys-
tems, Vienna, Austria).
Tubular epithelial cell proliferation and apoptosis
Tubular epithelial cell proliferation was determined as the number of
positively staining tubular nuclei in 15 randomly selected cortical
fields ( 160 magnification) for each rat, after immunostaining for
either Ki-67 or BrdU. Tubular epithelial cell apoptosis was
determined as the number of positively staining nuclei in 15
randomly selected cortical fields ( 160 magnification) from 8 rats
per group after TUNEL.20 Glomerular Ki-67 and BrdU immunos-
taining were determined by counting the number of positively
immunostaining nuclei in 30 glomerular profiles from each kidney
section (n¼ 9 per group).
Glomerular volume
Glomerular volume was calculated on 4-mm-thick periodic acid-
Schiff-stained kidney sections (30 glomerular profiles from each rat,
n¼ 12 per group) as described previously20 and using the formula:
GV ¼ ðb=kÞðGAÞ3=2
where b¼ 1.38 pertains to the sphere and k¼ 1.10 is the distribution
coefficient.55
Glomerular capillary volume
Glomerular capillary volume was estimated on kidney sections
labeled with a JG-12 monoclonal antibody.53 Kidney sections
were scanned using the Aperio ScanScope system (Aperio Techno-
logies, Vista, CA) and analyzed using ImageScope (Aperio
Technologies), with the magnitude of glomerular JG-12 immuno-
staining determined in 30 randomly selected glomerular profiles
from each kidney section. Data are expressed as fold change relative
to controls.
Statistics
Data are expressed as means±s.e.m. Statistical significance was
determined by one-way ANOVA (analysis of variance) with Tukey’s
post-test or Student’s t-test where appropriate. Two-way ANOVA
was performed for assessing the interaction between glycemic status
and treatment effect. All statistics were performed using GraphPad
Prism 5 for Mac OS X (GraphPad Software, San Diego, CA).
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